A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer

BACKGROUND: As the second-line chemotherapy for stage IV recurrent or nonresectable colorectal cancer, our hospital started a modified treatment regimen comprising of irinotecan plus S-1 (IRIS) [tegafur/gimeracil/oteracil (S-1)] plus molecular targeting agents (MTAs), i.e., an epidermal growth facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Higami, Shigeo, Mukai, Masaya, Yokoyama, Daiki, Uda, Syuji, Abe, Rin, Mamuro, Nana, Kishima, Kyoko, Hasegawa, Sayuri, Tajima, Takayuki, Nomura, Eiji, Makuuchi, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186548/
https://www.ncbi.nlm.nih.gov/pubmed/37201062
http://dx.doi.org/10.21037/jgo-22-899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186548/
https://www.ncbi.nlm.nih.gov/pubmed/37201062
http://dx.doi.org/10.21037/jgo-22-899

Ejemplares similares